Abstract 318: Preclinical evaluation of monoclonal antibody H6-11 for prostate cancer imaging

Altered post-translational modification (PTM) of glycosylations to various nuclear and cytosolic proteins is a universal feature of cancer cells and these modified glycan plan significant role in immune surveillance, tumor invasion, and increase malignancy. In this study, we reported a novel monoclonal antibody reacting to the tumor glycoproteins with molecular weight around 40-60 kDa. Deglycosylation examination suggested the antigenic isotope of the glycan is O-linked β-N-acetylglucosamine (O-GlcNAc) group. We examined the reactivity of H6-11 to cancer cells including PC-3, MCF-7 cells and implanted PC-3 and EMT-6 tumor tissues using immunofluorescence staining and autoradiography technique. The Zr-89 labeled H6-11 was successfully synthesized and the microPET study was performed in PC-3 xenograft prostate model in nude mice. microPET study showed that significant amount of radioactivity accumulation was observed in the excretory organs during the early period post-injection of radioactivity. At 24 hrs post-injection of radioactivity, significant amount of radioactivity was observed in the xenograft prostate tumor, while the radioactivity intensity was decreased in the liver and kidney. Radioactivity uptake in the tumor was still evident at 120 hrs post-injection of radioactivity. Our work suggested that the H6-11 antibody is capable of detecting prostate tumors both in vitro and in vivo. Citation Format: Hongjun Jin, Mai Xu, Prashanth K. Padakanti, Zhude Tu. Preclinical evaluation of monoclonal antibody H6-11 for prostate cancer imaging. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 318. doi:10.1158/1538-7445.AM2013-318